Intervention not reported
Primary patency · Individuals with peripheral arterial disease
The intervention probably leads to higher primary patency (moderate certainty).
1 finding from 1 review
Intervention not reported
Primary patency · Individuals with peripheral arterial disease
The intervention showed no clear difference in primary patency (high certainty).
1 finding from 1 review
Intervention not reported
Mortality within · Individuals with peripheral arterial disease
The intervention showed no clear difference in mortality within (high certainty).
1 finding from 1 review
Stroke · patients with hypertension
Enalapril plus folic acid leads to lower stroke compared with enalapril (high certainty).
1 finding from 1 review
First unstable angina pectoris episode requiring hospitalisation · patients with hypertension
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death from any cause · patients with hypertension
Enalapril plus folic acid showed no clear difference in death from any cause compared with enalapril (high certainty).
1 finding from 1 review
Serious adverse event (cancer) · patients with hypertension
Enalapril plus folic acid showed no clear difference in serious adverse event (cancer) compared with enalapril (moderate certainty).
1 finding from 1 review
Myocardial infarction · patients with hypertension
Enalapril plus folic acid showed no clear difference in myocardial infarction compared with enalapril (moderate certainty).
1 finding from 1 review
Intervention not reported
Systolic BP ‐ Aliskiren 75 mg vs. placebo · primary hypertension
1 finding from 1 review
Intervention not reported
Systolic BP ‐ Aliskiren 150 mg vs. placebo · primary hypertension
1 finding from 1 review
Intervention not reported
Systolic BP ‐ Aliskiren 300 mg vs. placebo · primary hypertension
1 finding from 1 review
Intervention not reported
Systolic BP ‐ Aliskiren 600 mg vs. placebo · primary hypertension
1 finding from 1 review
Intervention not reported
Diastolic BP ‐ Aliskiren 75 mg vs placebo · primary hypertension
1 finding from 1 review
Intervention not reported
Diastolic BP ‐ Aliskiren 150 mg vs placebo · primary hypertension
1 finding from 1 review
Intervention not reported
Diastolic BP ‐ Aliskiren 300 mg vs placebo · primary hypertension
1 finding from 1 review
Intervention not reported
Diastolic BP ‐ Aliskiren 600 mg vs placebo · primary hypertension
1 finding from 1 review
Intervention not reported
Diarrhoea ‐ Aliskiren 600 mg vs placebo · primary hypertension
The intervention may leads to higher diarrhoea ‐ Aliskiren 600 mg vs placebo (low certainty).
1 finding from 1 review
Intervention not reported
Death or major disability by 18 to 24 months corrected age (aligned definition) · extremely preterm infants
The intervention showed no clear difference in death or major disability by 18 to 24 months corrected age (aligned… (high certainty).
1 finding from 1 review
Intervention not reported
Death to 18 to 24 months corrected age · extremely preterm infants
The intervention leads to higher death to 18 to 24 months corrected age (high certainty).
1 finding from 1 review
Intervention not reported
Major disability by 18 to 24 months corrected age (aligned definition) · extremely preterm infants
The intervention showed no clear difference in major disability by 18 to 24 months corrected age (aligned definition) (high certainty).
1 finding from 1 review